Hualan Biological Vaccine Inc. (SHE:301207)

Market Cap	11.41B +10.2%
Revenue (ttm)	1.20B +6.6%
Net Income	182.92M -11.0%
EPS	0.31 -10.5%
Shares Out	595.00M
PE Ratio	62.36
Forward PE	n/a
Dividend	0.60 (3.13%)
Ex-Dividend Date	Oct 27, 2025

Volume	5,033,915
Average Volume	5,286,453
Open	18.43
Previous Close	18.62
Day's Range	18.37 - 19.19
52-Week Range	14.45 - 27.88
Beta	0.83
RSI	46.14
Earnings Date	Mar 28, 2026

About Hualan Biological Vaccine

Hualan Biological Vaccine Inc. engages in the research and development, production, and sale of vaccines and genetic engineering biological products in China. The company offers influenza vaccine (split virion), recombinant hepatitis B vaccine (hansenula polymorpha), meningococcal polysaccharide vaccine, influenza vaccine (split virion) quadrivalent, and meningococcal polysaccharide vaccine. It also sells self-produced products. The company was founded in 2005 and is based in Xinxiang, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 748
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301207

Financial Performance

In 2025, Hualan Biological Vaccine's revenue was 1.20 billion, an increase of 6.62% compared to the previous year's 1.13 billion. Earnings were 182.92 million, a decrease of -10.99%.